IGF-1, Sarcopenia and Mortality: a Cohort Study in Patient With Cognitive Impairment (ISAAC)

University of Roma La Sapienza

Status: Completed

Conditions: Cognitive Impairment; Insulin-like Growth Factor 1

Treatments: Procedure: IGF-1 serum value

Study type: Observational

Funder types: Other

Identifiers

NCT02139410

IGF-001

Details and patient eligibility

About

Insulin-like growth factor 1 (IGF)-1 is an important neuromyotrophic hormone. Disregulation of this hormone has been reported to influence the genesis of cognitive impairment and dementia in the elderly patients. We analyzed the possible link between IGF-1 and risk of Sarcopenia and Mortality in a cohort of elder patients with cognitive impairment.

Enrollment: 589 patients

Sex: All

Ages: 65 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of cognitive impairment (MMSE < 24)
• Age > 65 ys

Exclusion criteria

• Diagnosis of pancreatic disorders
• Diagnosis of acromegaly
• Diagnosis of GH-related disorders
• Recent bone fractures or immobility before the enrollment (3 months)
• Cancer

Trial design

589 participants in 2 patient groups

IGF-1 1st and 2nd quartile

Description:

Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment

Treatment:

Procedure: IGF-1 serum value

IGF-1 3rd and 4rd quartile

Description:

Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment

Treatment:

Procedure: IGF-1 serum value